1. Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer 
Thomas Muley, PhD, Hendrik Dienemann, MD, PhD, Felix JF Herth, MD, PhD, Michael Thomas, MD, PhD, Michael Meister, PhD, Joachim Schneider, MD, PhD 
Journal of Thoracic Oncology 
Volume 8, Issue 7, Pages (July 2013)
DOI: /JTO.0b013e31828f696b
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Scatterplot of mesothelin versus CEA in the study population (both axes in logarithmic scale). CEA, carcinoembryonic antigen; MPM, malignant pleural mesothelioma.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828f696b)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Boxplot of CEA, mesothelin, and the quotient mesothelin/CEA in the various study groups. The results of pairwise comparison (two–tailed Mann–Whitney U test) are given in the tables. CEA, carcinoembryonic antigen; LC, lung cancer; MPM, malignant pleural mesothelioma.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828f696b)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Receiver operating chracteristic curves for the comparison of MPM versus lung cancer (left) and for MPM versus benign asbestos disease (right) for mesothelin alone, for CEA, and for the quotient mesothelin/CEA. MPM, malignant pleural mesothelioma; AUC, area under the curve.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828f696b)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions